Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 283

1.

Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.

Choi CH, Chung JY, Kang JH, Paik ES, Lee YY, Park W, Byeon SJ, Chung EJ, Kim BG, Hewitt SM, Bae DS.

Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30153-0. doi: 10.1016/j.ygyno.2020.02.017. [Epub ahead of print]

PMID:
32107047
2.

Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.

Choi HJ, Lee YY, Choi CH, Kim TJ, Lee JW, Bae JH, Bae DS, Kim BG.

Curr Probl Cancer. 2020 Feb 12:100557. doi: 10.1016/j.currproblcancer.2020.100557. [Epub ahead of print]

PMID:
32067746
3.

Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer.

Choi CH, Choi HJ, Lee JW, Kang ES, Cho D, Park BK, Kim YM, Kim DY, Seo H, Park M, Kim W, Choi KY, Oh T, Kang CY, Kim BG.

J Clin Med. 2020 Jan 5;9(1). pii: E147. doi: 10.3390/jcm9010147.

4.

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.

Jeong SY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS, Lee YY.

J Ovarian Res. 2019 Dec 31;13(1):1. doi: 10.1186/s13048-019-0602-5.

5.

Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea.

Seo JH, Jeong SY, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH.

Obstet Gynecol Sci. 2019 Nov;62(6):411-419. doi: 10.5468/ogs.2019.62.6.411. Epub 2019 Oct 11.

6.

CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.

Kim J, Cho YJ, Ryu JY, Hwang I, Han HD, Ahn HJ, Kim WY, Cho H, Chung JY, Hewitt SM, Kim JH, Kim BG, Bae DS, Choi CH, Lee JW.

Gynecol Oncol. 2020 Jan;156(1):211-221. doi: 10.1016/j.ygyno.2019.11.004. Epub 2019 Nov 24.

PMID:
31776040
7.

Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.

Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW.

Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3.

8.

Comparison between Laparoendoscopic Single-Site and Conventional Laparoscopic Surgery in Mature Cystic Teratoma of the Ovary.

Kim MS, Choi CH, Lee JW, Kim BG, Bae DS, Kim TJ.

Gynecol Minim Invasive Ther. 2019 Oct 24;8(4):155-159. doi: 10.4103/GMIT.GMIT_3_19. eCollection 2019 Oct-Dec.

9.

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS.

N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.

10.

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study.

Paik ES, Lee YJ, Lee JY, Shin W, Park SY, Kim SI, Kim JW, Choi CH, Kim BG.

J Clin Med. 2019 Nov 8;8(11). pii: E1920. doi: 10.3390/jcm8111920.

11.

Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.

Choi HJ, Lee YY, Sohn I, Kim YM, Kim JW, Kang S, Kim BG.

Curr Probl Cancer. 2019 Nov 1:100508. doi: 10.1016/j.currproblcancer.2019.100508. [Epub ahead of print] Review.

PMID:
31708114
12.

Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status.

Jeong SY, Park H, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH.

Cancer Res Treat. 2019 Oct 29. doi: 10.4143/crt.2019.328. [Epub ahead of print]

13.

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.

Lee JY, Yi JY, Kim HS, Lim J, Kim S, Nam BH, Kim HS, Kim JW, Choi CH, Kim BG; KGOG investigators.

Jpn J Clin Oncol. 2019 Aug 1;49(8):789-792. doi: 10.1093/jjco/hyz085.

PMID:
31671191
14.

Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer.

Lee YY, Cho YJ, Shin SW, Choi C, Ryu JY, Jeon HK, Choi JJ, Hwang JR, Choi CH, Kim TJ, Kim BG, Bae DS, Park W, Lee JW.

Sci Rep. 2019 Oct 28;9(1):15394. doi: 10.1038/s41598-019-51959-3.

15.

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.

Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG; KGOG investigators.

J Gynecol Oncol. 2019 Nov;30(6):e112. doi: 10.3802/jgo.2019.30.e112.

16.

Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.

Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, Walther A, Zheng J, Fasching P, Zheng W, Yin Ling W, Park SK, Kim BG, Choi JY, Park B, Davey Smith G, Martin RM, Lewis SJ.

PLoS Med. 2019 Aug 7;16(8):e1002893. doi: 10.1371/journal.pmed.1002893. eCollection 2019 Aug.

17.

Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods.

Paik ES, Lee JW, Park JY, Kim JH, Kim M, Kim TJ, Choi CH, Kim BG, Bae DS, Seo SW.

J Gynecol Oncol. 2019 Jul;30(4):e65. doi: 10.3802/jgo.2019.30.e65. Epub 2019 Mar 11.

18.

In Vivo Comparison of MONOFIX, A Novel Barbed Suture with a Triangular Stopper, with Pre-existing Products in a Porcine Model.

Kim J, Eom HJ, Shin H, Jeong SY, Kim MS, Yoon HS, In CH, Kim BG, Bae DS, Lee JW.

J Minim Invasive Gynecol. 2020 Feb;27(2):473-481. doi: 10.1016/j.jmig.2019.04.005. Epub 2019 Apr 6.

PMID:
30959198
19.

Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases.

Paik ES, Kang JH, Kim J, Lee YJ, Choi CH, Kim TJ, Kim BG, Bae DS, Lee JW.

Obstet Gynecol Sci. 2019 Mar;62(2):103-111. doi: 10.5468/ogs.2019.62.2.103. Epub 2019 Feb 12.

20.

Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.

Lawrenson K, Song F, Hazelett DJ, Kar SP, Tyrer J, Phelan CM, Corona RI, Rodríguez-Malavé NI, Seo JH, Adler E, Coetzee SG, Segato F, Fonseca MAS, Amos CI, Carney ME, Chenevix-Trench G, Choi J, Doherty JA, Jia W, Jin GJ, Kim BG, Le ND, Lee J, Li L, Lim BK, Adenan NA, Mizuno M, Park B, Pearce CL, Shan K, Shi Y, Shu XO, Sieh W; Australian Ovarian Cancer Study Group, Thompson PJ, Wilkens LR, Wei Q, Woo YL, Yan L, Karlan BY, Freedman ML, Noushmehr H, Goode EL, Berchuck A, Sellers TA, Teo SH, Zheng W, Matsuo K, Park S, Chen K, Pharoah PDP, Gayther SA, Goodman MT.

Gynecol Oncol. 2019 May;153(2):343-355. doi: 10.1016/j.ygyno.2019.02.023. Epub 2019 Mar 19.

Supplemental Content

Loading ...
Support Center